A study for a 48 year old woman who takes Zantac 150, Flecainide Acetate - from FDA reports

5 females aged 48 (±5) who take the same drugs are studied. This is a personalized study for a 48 year old female patient who has Gerd, A-Fib. The study is created by eHealthMe based on reports from FDA.

How to use this study: bring a copy to your health teams to ensure drug risks and benefits are fully discussed and understood.

Peer to Peer mobile support

Peer support for this study is available on our Ginger Health app. It's free, anonymous and secure. The app is ideal for people taking multiple medications or having multiple conditions.

On Jan, 12, 2019

5 females aged 48 (±5) who take Zantac 150, Flecainide Acetate are studied.

Number of reports submitted per year:

Zantac 150, Flecainide Acetate for a 48-year old woman.

Information of the patient in this study:

  • Age: 48
  • Gender: female
  • Conditions: Gerd, A-Fib
  • Drugs taken:
    • Zantac 150 (ranitidine hydrochloride)
    • Flecainide Acetate (flecainide acetate)

eHealthMe real world results:

Most common drug interactions over time

< 1 month:
1 - 6 months:
6 - 12 months:
1 - 2 years:
2 - 5 years:
  1. Intestinal obstruction
5 - 10 years:
10+ years:
not specified:
  1. Hepatitis (inflammation of the liver)
  2. Difficulty in walking
  3. Muscle aches (muscle pain)
  4. Intestinal obstruction

Top conditions involved for these people *:

  1. Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 3 people, 60.00%
  2. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 3 people, 60.00%
  3. Vitamin Supplementation : 1 person, 20.00%
  4. Oral Herpes (viral infection of mouth): 1 person, 20.00%
  5. Low Density Lipoprotein Increased (cholesterol increased in blood): 1 person, 20.00%
  6. Iron Deficiency Anaemia : 1 person, 20.00%
  7. Insomnia (sleeplessness): 1 person, 20.00%
  8. Haemorrhoids (a swollen vein or group of veins in the region of the anus): 1 person, 20.00%
  9. Crohn's Disease (condition that causes inflammation of the gastrointestinal tract): 1 person, 20.00%
  10. Abdominal Pain Upper : 1 person, 20.00%

Top co-used drugs for these people *:

  1. Clopidogrel (3 people, 60.00%)
  2. Pradaxa (2 people, 40.00%)
  3. Paroxetine Hydrochloride (2 people, 40.00%)
  4. Vesicare (2 people, 40.00%)
  5. Keppra (2 people, 40.00%)
  6. Citicoline (1 person, 20.00%)
  7. Clinoril (1 person, 20.00%)
  8. Detrol La (1 person, 20.00%)
  9. Humira (1 person, 20.00%)
  10. Levetiracetam (1 person, 20.00%)

* Some reports may have incomplete information.

You are not alone:

What are the drugs?

What are the conditions?

Related studies:

FDA reports used in this study

Recent updates

Recent general studies
Recent personal studies

NOTE: The study is based on active ingredients. Other drugs that have the same active ingredients are also considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Submit your testimonial

  • Please fill in your Testimonial.
  • Please enter a minimum of 10 characters for your Testimonial.
  • Please fill in your Name.

Please wait...


Thank you!